© 2020 MJH Life Sciences and HCPLive. All rights reserved.
Gastroenterology
Ozanimod Could be an Alternative to Anti-TNF Drugs for Crohn's Disease
June 30, 2020
Article
Ozanimod could soon be added to the ever growing stable of potential treatments for Crohn’s disease.
FDA Halts NASH Treatment Application
June 29, 2020
Article
The FDA recommends additional safety and efficacy data from the ongoing REGENERATE trial.
C. Diff Infection Diagnosis Increases Risk for Family Members
June 28, 2020
Article
Prior family exposure represented the factor with the second highest IRR behind hospital exposure.
Enhanced Treatment Endpoints Leads to Lower Risk of Ulcerative Colitis Relapse
June 24, 2020
Article
The median 12-month risk of clinical relapse in patients with MES 1 was 28.7%, while the estimated annual risk of clinical relapse in patients with a MES 0 was 13.7%.
Upadacitinib Leads to Clinical Remission in Crohn's Disease
June 16, 2020
Article
During the induction period, patients in the treatment group had higher incidences of infections and serious infectious compared to placebo.
Ildiko Lingvay, MD: Predictors of Gastrointestinal Events with Semaglutide
June 12, 2020
Article
A recent analysis is examining potential factors associated with adverse gastrointestinal events in patients using semaglutide and whether it mitigates benefit.
Vibeke Strand, MD: Comorbidities Make Treating Psoriatic Arthritis Difficult
June 11, 2020
Article
Dr. Vibeke Strand discusses how better treatment of psoriatic arthritis could yield better treatments for NASH.
NASH Indications Increasing Amongst Patients in Need of a Liver Transplant
June 10, 2020
Article
Between 2002-2019, NASH is the leading liver indication for women without HCC.
AGA Releases New Guidelines for Probiotic Use in Gastroenterology
June 10, 2020
Video
New recommendations support the use of probiotics for preterm and low birthweight infants to prevent mortality and necrotizing enterocolitis.
Dennis McGonagle, PhD: The Future of Guselkumab for Psoriatic Arthritis
June 08, 2020
Article
Dr. Dennis McGonagle said guslekumab is also being tested in patients with inflammatory bowel disease.